These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1218 related items for PubMed ID: 27707549

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Predictors of Outcome in Patients with Neovascular Age-Related Macular Degeneration Switched from Ranibizumab to 8-Weekly Aflibercept.
    Chatziralli I, Nicholson L, Vrizidou E, Koutsiouki C, Menon D, Sergentanis TN, Citu MC, Hamilton R, Patel PJ, Hykin P, Sivaprasad S.
    Ophthalmology; 2016 Aug; 123(8):1762-1770. PubMed ID: 27289179
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
    Despreaux R, Cohen SY, Semoun O, Zambrowski O, Jung C, Oubraham H, Souied EH.
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effectiveness of Continued Ranibizumab Therapy in Neovascular Age-Related Macular Degeneration versus Switch to Aflibercept: Real World Evidence.
    Chakravarthy U, Bezlyak V, Sagkriotis A, Griner R, Skelly A, Boyer DS, Milnes F.
    Ophthalmol Retina; 2019 Jan; 3(1):8-15.e1. PubMed ID: 30929819
    [Abstract] [Full Text] [Related]

  • 11. Indocyanine green angiography findings in patients with neovascular age-related macular degeneration refractory to ranibizumab switched to aflibercept.
    Calvo-Gonzalez C, Reche-Frutos J, Fernández-Vigo JI, Donate-López J, Serrano-García I, Fernández-Pérez C.
    Int Ophthalmol; 2019 Nov; 39(11):2441-2448. PubMed ID: 30767090
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Characterization of Poor Visual Outcomes of Neovascular Age-related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
    Nguyen CL, Gillies MC, Nguyen V, Daien V, Cohn A, Banerjee G, Arnold J, Fight Retinal Blindness! Study Group.
    Ophthalmology; 2019 May; 126(5):735-742. PubMed ID: 30529685
    [Abstract] [Full Text] [Related]

  • 14. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry.
    Rao P, Lum F, Wood K, Salman C, Burugapalli B, Hall R, Singh S, Parke DW, Williams GA.
    Ophthalmology; 2018 Apr; 125(4):522-528. PubMed ID: 29146306
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab.
    Narayan DS, Muecke J.
    Indian J Ophthalmol; 2015 Nov; 63(11):832-6. PubMed ID: 26669334
    [Abstract] [Full Text] [Related]

  • 17. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.
    Brynskov T, Munch IC, Larsen TM, Erngaard L, Sørensen TL.
    Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617
    [Abstract] [Full Text] [Related]

  • 18. A pharmacoepidemiologic study of ranibizumab and aflibercept use 2013-2016. The Fight Retinal Blindness! Project.
    Barthelmes D, Nguyen V, Walton R, Gillies MC, Daien V, Fight Retinal Blindness Study Group.
    Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1839-1846. PubMed ID: 30051312
    [Abstract] [Full Text] [Related]

  • 19. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
    Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Ng P, Pecheur FL, McAllister IL.
    JAMA Ophthalmol; 2019 Apr 01; 137(4):372-379. PubMed ID: 30676617
    [Abstract] [Full Text] [Related]

  • 20. CONVERSION TO AFLIBERCEPT THERAPY VERSUS CONTINUING WITH RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEPENDENT ON MONTHLY RANIBIZUMAB TREATMENT.
    Mantel I, Gianniou C, Dirani A.
    Retina; 2016 Jan 01; 36(1):53-8. PubMed ID: 26166797
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 61.